S-1/A: Picard Medical Launches Public Offering Amidst Losses

Picard Medical, Inc. is offering up to 21.1 million shares of common stock and associated warrants to raise approximately $9.1 million, facing significant net losses and a going concern doubt.

Summary

• Picard Medical, Inc. (PMI) is conducting a public offering of up to 21,114,865 shares of common stock, 21,114,865 Series A Common Warrants, and 21,114,865 Series B Common Warrants, with an assumed combined public offering price of $0.4736 per share and accompanying warrants.
• The offering also includes Pre-Funded Warrants for purchasers whose beneficial ownership would exceed 4.99% (or 9.99% by election) of outstanding common stock, exercisable at $0.0001 per share.
• PMI expects to receive net proceeds of approximately $9.1 million from this offering, after deducting estimated Placement Agent fees and offering expenses.
• The company reported a net loss of $27.0 million for the year ended December 31, 2025, an increase from $21.1 million in 2024.
• Total revenues increased by 13% to $4.94 million in 2025 from $4.39 million in 2024, driven by a $1.0 million increase in USA sales, partially offset by decreases in other regions.
• Cost of revenues increased by 14% to $5.14 million in 2025, resulting in a gross loss of $0.2 million, an 82% increase from the $0.112 million gross loss in 2024.
• Research and development expenses decreased by 10% to $3.05 million in 2025, while selling, general and administrative expenses decreased by 2% to $10.0 million.
• Total other expenses significantly increased by 86% to $13.71 million in 2025, primarily due to derivative losses, interest expense, and financing charges related to debt and warrants.
• PMI's independent registered public accounting firm has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company's primary product, the SynCardia Total Artificial Heart (TAH), is the only FDA and Health Canada approved TAH, with over 2,100 implants across 27 countries.
• PMI is developing next-generation technologies, including the fully implantable Emperor TAH and the portable Unicorn driver, and is pursuing expanded U.S. label indications and international regulatory approvals.
• The company voluntarily withdrew its CE Mark certificate under the MDD in July 2022 and is working towards CE Mark certification under the new MDR framework, with submission expected in 2027.
• A securities class action lawsuit was filed against PMI in February 2026, alleging violations of federal securities laws related to its IPO and subsequent disclosures.
• PMI has significant customer concentrations, with Customer A accounting for 43% of total revenue in 2025 and 41% in 2024, and Customer B accounting for 13% in 2025 and 11% in 2024.
• The company relies on single-source suppliers for crucial components of its drivers and SynHall Valves, posing a supply chain risk.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant ongoing financial losses, a 'going concern' warning from auditors, and missed debt payments, which overshadow promising product development and market positioning.

Positives

• The SynCardia TAH is the only U.S. FDA and Health Canada approved Total Artificial Heart, with over 2,100 implants in 27 countries, demonstrating established clinical use.
• Clinical studies show strong efficacy, with 1-year survival rates ranging from 75% to 86.6% for patients implanted with the SynCardia TAH as a bridge to transplant.
• The company is actively developing next-generation technologies, including the fully implantable Emperor TAH and the portable Unicorn driver, with promising early prototype results (e.g., pulsatile flow rates exceeding minimum requirements, high durability, low energy consumption for Emperor).
• PMI holds six awarded U.S. and international patents and has over twelve pending applications, including new patents for its next-generation TAH technology.
• The company successfully completed its most recent Medical Device Single Audit Programs (MDSAP) audit in June 2025, with no deficiencies noted.
• Revenues increased by 13% in 2025 compared to 2024, primarily driven by increased sales in the USA.
• The FDA approved revisions to the SynCardia TAH indications for use in November 2024, removing 'temporary' language, which could facilitate broader adoption.
• PMI is pursuing expanded U.S. label indications (bridge to candidacy, long-term support) and international regulatory approvals (CE Mark under MDR, NMPA in China), which could significantly expand market opportunities.
• The company has a structured physician and clinical team training program, with over 30 centers certified to implant the SynCardia TAH.

Negatives

• PMI has a history of significant net losses, reporting $27.0 million in 2025 and $21.1 million in 2024, and expects to continue incurring losses for the foreseeable future.
• The company's independent registered public accounting firm has raised substantial doubt about its ability to continue as a going concern.
• The April 1, 2026, redemption payment for the Senior Secured Note has not been made, indicating potential liquidity issues.
• Gross loss increased by 82% to $0.2 million in 2025, and total cost of revenues as a percentage of total sales was 104% in 2025 and 103% in 2024, indicating an unprofitable cost structure.
• Total other expenses increased significantly by 86% to $13.71 million in 2025, largely due to non-cash derivative losses and financing charges.
• The company relies on a limited number of products (SynCardia TAH) for substantially all revenue, making it vulnerable to declines in sales or market acceptance.
• Manufacturing the SynCardia TAH requires highly specialized knowledge and skills, and the loss of key personnel could lead to production delays.
• PMI depends on single-source suppliers for many critical components of its drivers and SynHall Valves, creating supply chain risks and potential regulatory hurdles if alternative suppliers are needed.
• The company voluntarily withdrew its CE Mark certificate in Europe in July 2022 due to post-market surveillance documentation deficiencies, limiting its ability to market products in the EU.
• A securities class action lawsuit was filed in February 2026, alleging materially false or misleading statements in connection with the IPO and subsequent disclosures.
• PMI has significant customer concentrations, with a few customers accounting for a substantial portion of revenues and accounts receivable.
• The company is a 'controlled company' under NYSE rules, which may limit protections for stockholders compared to companies subject to full corporate governance requirements.
• PMI does not intend to pay cash dividends for the foreseeable future, retaining earnings for business development and expansion.

Risks

• History of significant losses and inability to achieve and sustain profitability, leading to substantial doubt about continuing as a going concern.
• Reliance on a limited number of products (SynCardia TAH) for substantially all revenue, making the business vulnerable to sales declines or lack of market acceptance.
• Manufacturing process requires highly specialized knowledge and operator skills, posing risks to timely production and quality standards.
• Dependence on specialized, single-source suppliers for critical components (e.g., driver components, SynHall Valves), with potential for supply interruptions and regulatory delays for new suppliers.
• Unproven future demand for current and new products, and potential reluctance of hospitals, surgeons, or patients to adopt SynCardia TAH.
• Inability to educate physicians on safe and effective use of SynCardia TAH and its implantation procedure, hindering growth.
• Failure to develop and retain a direct sales force and effective international distributor network.
• Operating in a market segment subject to rapid technological change, with competitors potentially developing safer, more effective, or less costly products.
• Significant customer concentrations and lack of long-term exclusive agreements with customers, leading to revenue fluctuations.
• Inability to successfully complete pre-clinical studies or clinical trials for new products or enhancements, limiting regulatory approvals.
• Premarket approvals for therapeutic medical devices could be denied or significantly delayed, impacting product commercialization.
• Extensive post-marketing regulation by the FDA and foreign authorities, leading to significant compliance costs and potential enforcement actions.
• Inadequate coverage and reimbursement from third-party payors for product use, negatively impacting revenues.
• Manufacturing operations, R&D, and corporate headquarters are at a single location, exposing the company to risks from disasters or disruptions.
• Product liability claims, recalls, and product deficiencies could damage reputation, incur substantial costs, and delay clinical trials.
• Claims related to improper handling, storage, or disposal of hazardous chemicals and biomaterials.
• International operations subject to political, economic, social instability, trade policies, and sanctions, impacting results.
• Credit risk from accounts receivable, especially in foreign countries with economic turmoil.
• Changes in U.S. and foreign tax laws could materially affect financial position and results.
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes.
• Inaccurate industry and market-related estimates.
• Inability to attract and retain highly qualified personnel.
• Risks associated with acquiring other companies or businesses, including integration difficulties and potential dilution.
• Failure to protect information technology infrastructure against cyber-based attacks, security breaches, or data corruption.
• Cybersecurity risks associated with using the device could endanger patient safety and marketability.
• Demand for total artificial hearts depends on factors like rising heart disorders, market need for alternatives to transplants, industry competition, and medical advances that could provide permanent solutions.
• Off-label use or misuse of products could harm market image, lead to product liability suits, and regulatory sanctions.
• Non-compliance with medical device reporting (MDR) requirements, leading to corrective actions or agency enforcement.
• Misconduct by employees, contractors, or partners, including non-compliance with regulatory standards and fraud/abuse laws.
• Failure to obtain approval for long-term indications (2 years or more) for SynCardia TAH in the U.S. within the next year, potentially requiring additional clinical trials.
• Failure to reinstate CE certificate under CE MDR in Europe, limiting market access.
• Prior weaknesses in CE MDD regulatory regime and compliance with EU medical device regulations.
• Many aspects of SynCardia TAH are no longer patent-protected, relying on trade secrets and know-how, which could be challenged or misappropriated.
• Extensive patent and intellectual property litigation in the medical device industry, potentially leading to costly litigation, diversion of management attention, damages, or royalty payments.
• Potential claims of inadvertent or intentional use/disclosure of trade secrets from former employers by employees.
• Share price volatility and substantial losses for investors.
• Broad discretion of management over the use of net proceeds from the offering.
• Future issuances of common stock or the perception thereof may cause market price to decline and dilute existing stockholders.
• No public market for Pre-Funded Warrants or Common Warrants, limiting liquidity.
• Holders of Pre-Funded Warrants and Common Warrants have no stockholder rights until exercise.
• Beneficial ownership limitations may prevent significant holders from exercising Pre-Funded Warrants.
• Exercise of outstanding warrants and stock options may adversely affect trading price and dilute stockholders.
• Increased costs and regulations as a public company, diverting management time and potentially lowering profits.
• Status as an emerging growth company and smaller reporting company may make securities less attractive.
• Potential for securities class action or derivative litigation.
• Charter designates specific courts as exclusive forum for stockholder litigation, potentially limiting stockholders' ability to obtain a favorable forum.

Future Outlook

PMI is focused on developing the fully implantable Emperor TAH, with FDA approval potentially as early as 2029, and the next-generation Unicorn driver, with regulatory testing expected in the second half of 2026 and FDA approval by mid-2027. The company anticipates FDA approval for the upgraded Freedom+ Driver by the end of 2026 and expects to gain FDA approvals for next-generation Freedom and C2 Drivers in Q2 2026 and 2028, respectively. A decision from the FDA regarding expanded indications for the SynCardia TAH (removing 'imminent death' language and adding 'bridge to candidacy') is expected in Q3 2026. PMI also plans to pursue CE Mark certification under the MDR framework in the EU, with submission expected in 2027, and NMPA approval in China, with initial feedback expected in 2026 and approval within 18 months from filing. The company aims to improve manufacturing efficiency, reduce production costs, and expand sales, marketing, and distribution capabilities globally.

Management Comments

• Patrick NJ Schnegelsberg, Chief Executive Officer, has over 25 years of executive leadership experience in the medical device sector and believes in the 'ironman heart' vision for SynCardia TAH.
• Bernard Skaggs, Chief Financial Officer, has over 30 years of experience in finance and accounting.
• Matt Schuster, Chief Operating Officer, has played a key role in development projects for SynCardia, including the 50cc TAH and next-generation pneumatic driver.
• Management believes that the present and projected demand for SynCardia TAHs depends on factors such as rising heart-related disorders, the market need for short-term and long-term alternatives to heart transplants, industry competition, and medical advances.
• Management acknowledges the need to scale up the business to offset large fixed overhead costs and is investing heavily in new product development and regulatory approvals.

Industry Context

StockSavvy.ai notes that Picard Medical operates in the critical and evolving advanced heart failure market, where its SynCardia TAH holds a unique position as the only FDA and Health Canada approved total artificial heart. The competitive landscape includes alternative mechanical circulatory support (MCS) therapies like Left Ventricular Assist Devices (LVADs) from larger companies such as Abbott (e.g., HeartMate 3), extracorporeal membrane oxygenation (ECMO) systems, and percutaneous axial flow ventricular assist devices (e.g., Impella system). While these alternatives primarily support one ventricle and are often limited to hospital use, SynCardia's TAH replaces both ventricles and allows for outpatient use with the portable Freedom Driver. The industry is characterized by rapid technological change and extensive regulatory hurdles, with other TAH developers like CARMAT SA facing financial distress and BiVACOR Inc. in early-stage clinical testing. PMI's strategy to develop fully implantable and next-generation portable drivers aligns with broader industry trends towards less invasive and more patient-friendly solutions, but it faces significant capital requirements and regulatory uncertainties.

Comparison to Industry Standards

• **SynCardia TAH vs. CARMAT Aeson vs. BiVACOR:** SynCardia TAH is the only TAH approved for commercial use in the US and Canada, with over 2,100 implants as of March 2026. CARMAT's Aeson TAH has received CE Mark approval in Europe (under MDD 2020, MDR 2025) but has only 108 implants as of March 2026 and is facing insolvency proceedings. BiVACOR is in early-stage human clinical testing with 6 implants as of March 2026 and no commercial approval.
• **Implant Size and Weight:** SynCardia TAH (50cc and 70cc) has a total implant size of 250-400ml and weight of 200-240g, designed to serve men, women, and children. In contrast, Carmat's Aeson is 750ml and 900g, potentially not fitting smaller patients, and BiVACOR's is 400ml and approximately 512g.
• **Cardiac Output:** SynCardia TAH generates cardiac output up to 10.5 L/min (70cc) and 7.5 L/min (50cc), exceeding the average human heart's 5.6 L/min and the critical minimum of 2.5-3.0 L/min for perfusion.
• **Reimbursement:** SynCardia TAH implantation is covered by CMS under DRG 001, the highest reimbursement category for cardiac procedures, with payments ranging from $187,000 to $482,000. This is comparable to LVAD implantation procedures (also DRG 001, $187,000-$482,000), and significantly higher than ECMO ($181,000 under DRG 003) or temporary axial flow assist devices ($117,000-$52,000 under DRG 215/221).
• **Competing Device Average Selling Prices:** Abbott HeartMate 3 LVAD is approximately $120,000, Abiomed Impella devices are $25,000-$30,000, and Getinge CardioHelp ECMO system is approximately $111,000. The filing does not provide a direct selling price for SynCardia TAH, but the reimbursement figures suggest a higher overall procedure cost, reflecting its comprehensive heart replacement function.

Corporate Governance

Legal Proceedings

• On February 2, 2026, a putative securities class action lawsuit, 'Louie v. Picard Medical, Inc., et al.,' Case No. 5:26-CV-01024, was filed in the United States District Court for the Northern District of California, San Jose Division.
• The complaint names PMI and certain current/former officers and directors as defendants, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5.
• The alleged class period is from September 2, 2025, through October 31, 2025.
• The lawsuit generally alleges that defendants made materially false or misleading statements or omissions in connection with the company's initial public offering and subsequent public disclosures, and that the company's securities were affected by social-media-based promotion activity.
• PMI believes the claims are without merit and intends to defend the matter vigorously.
• Given the early stage of proceedings, the outcome is inherently uncertain, and PMI cannot reasonably estimate a possible loss or range of loss.

Related Party Transactions

• On December 31, 2025, the company wrote off a $137,000 receivable from Versa Capital Management, LLC (affiliated with Sindex SSI Financing, LLC, a former 100% owner of SynCardia), which was an unsecured promissory note from September 27, 2021.
• Multiple loans from Fang Family Fund, LLC and Fang Family Fund II, LLC (entities affiliated with director Richard Fang) were consolidated into a $7.0 million convertible note (FFF Convertible Note) on July 2, 2024, bearing 6% simple interest.
• The FFF Convertible Note was donated by Richard Fang to Nexus Science Foundation Inc. and Another Dimension Foundation on November 12, 2024, and subsequently converted into 4,054,517 common shares for each entity on September 2, 2025.
• Various interest-free and interest-bearing loans from Fang Family Fund II, LLC were made and repaid between January 2024 and September 2025, totaling several million dollars.
• On August 20, 2024, the company borrowed $250,000 from Hunniwell (an entity affiliated with an executive director) under an interest-free loan, which was later amended to the terms of the Senior Secured Notes and repaid on September 9, 2025, along with interest.
• A $93,633 loan to Hunniwell for travel expense reimbursements and a $187,190 loan to Daniel Teo (for severance from prior employment) were issued on July 1, 2025, under the same terms as the Senior Secured Notes and repaid on September 9, 2025.
• On November 26, 2025, the company borrowed $1.0 million from Fang Family Fund I, LLC, bearing 6% interest per annum, due November 27, 2026, and secured by all company assets. This loan was repaid on January 6, 2026, offset by a $134,712 related party note receivable (overpaid interest).
• On February 28, 2026, the company borrowed $0.7 million from Fang Family Fund I, LLC, bearing 6% interest per annum, due November 27, 2026.
• The company's related person transaction policy requires review and approval/ratification of transactions exceeding $120,000 or 1% of average total assets by the audit committee.

Stakeholder Impact

• **Shareholders:** Will experience immediate dilution from the current public offering and potential future exercises of warrants and options. The 'going concern' doubt and significant losses pose a high risk to investment value. The securities class action lawsuit could also negatively impact share price and company resources.
• **Employees:** The company's ability to attract and retain highly qualified personnel is crucial for future success, especially in specialized manufacturing and R&D. Continued losses and financial instability could affect employee morale and retention.
• **Customers (Hospitals/Surgeons):** The company's ability to maintain regulatory approvals, ensure product quality, and provide adequate training is vital for continued adoption and use of the SynCardia TAH. Product deficiencies or recalls could damage trust and reduce usage.
• **Suppliers:** Reliance on single-source suppliers for critical components creates risk for the company's operations, which could in turn impact suppliers if PMI faces financial difficulties or changes sourcing strategies.
• **Creditors:** The 'going concern' doubt and missed debt payments (e.g., April 1, 2026, Senior Secured Note payment) indicate elevated risk for creditors. The Senior Secured Noteholders have a first priority lien on all tangible and intangible assets.
• **Regulatory Bodies:** The company's ongoing efforts to obtain and maintain regulatory approvals (FDA, CE Mark, NMPA) and address compliance issues (e.g., CE Mark withdrawal, cannula tears) are critical for market access and operational continuity. Failure to comply could lead to enforcement actions.

Next Steps

• Continue development of the Emperor Total Artificial Heart, with FDA approval potentially as early as 2029.
• Fund development of the next-generation Unicorn driver, with regulatory testing expected in the second half of 2026 and FDA approval by mid-2027.
• Support efforts to expand approved indications for use of the SynCardia TAH (remove 'imminent death' language, add 'bridge to candidacy'), with an FDA decision expected in Q3 2026.
• Pursue CE Mark certification in the European Union under the Medical Device Regulation (MDR) framework, with submission expected in 2027.
• Evaluate regulatory approval pathways with the National Medical Products Administration (NMPA) in China, with initial feedback expected in 2026 and approval within 18 months from filing.
• Fund initiatives to improve manufacturing efficiency and reduce production costs, including potential collaboration with SynCardia Medical Beijing, Inc. (SMB).
• Build sales, marketing, and distribution capabilities for the SynCardia TAH system in the United States and internationally.
• Address the potential for cannula tears in the SynCardia TAH by completing process validation for a design change and submitting a 180-day PMA Supplement to the FDA in Q3 2026.
• Continue animal trials for the Emperor TAH in the first half of 2026.
• Develop upgraded Freedom and C2 Drivers, with FDA approvals expected in Q2 2026 and 2028, respectively.
• Remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Picard Medical faces severe financial distress, evidenced by significant recurring net losses ($27.0 million in 2025), a 'going concern' warning from its auditors, and a missed debt payment on its Senior Secured Note. While the company possesses a unique FDA-approved product and a promising R&D pipeline, its current financial instability, high cost of revenue, reliance on single-source suppliers, and ongoing regulatory challenges (including the voluntary withdrawal of its CE Mark in Europe) present substantial risks. The current public offering, while providing some capital, is insufficient to fully address the underlying financial issues and the dilution to existing shareholders is significant. The securities class action lawsuit further adds to the uncertainty. A seasoned investor would view these factors as indicative of a company with a very high risk of failure or significant further value erosion, making a 'strong sell' recommendation appropriate.

Keywords

Total Artificial Heart, TAH, SynCardia, Medical Device, Heart Failure, Bridge to Transplant, Emperor TAH, Unicorn Driver, FDA Approval, CE Mark, NMPA China, Public Offering, Warrants, Biotechnology, Cardiovascular, Medical Technology, SEC Filing, Going Concern, Dilution, Intellectual Property